The consensus price target hints at a 29.6% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

Here are three stocks with buy rank and strong value characteristics for investors to consider today, March 3rd: EMCOR Group, ...

The Fund’s largest detractors from performance in the fourth quarter included Jazz Pharmaceuticals, Boyd Gaming, Park Hotels ...

Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report ...

Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...

Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...

Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating ...

New York State Common Retirement Fund lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) ...

Cantor downgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) to neutral from overweight, citing the company's increasing focus on ...

Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...

We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...